Morningstar® Stock Report™

Pfizer Inc PFE

Último Precio
26.00
Cambio del día
0.61|2.40%

a 19/04/2024
19:59:26 EDT | USD  Retraso mínimo: 15 minutos

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
25.85 - 25.9325.35 - 26.0038,372,80142,721,446147.20Bil
Último Cierre52 Week RangeP/UDividendo %ISIN
25.3925.23 - 40.3770.276.35US7170811035

Cotización Pfizer Inc

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
Más...
Cuenta de Resultados
Ingresos81,288.00100,330.0058,496.00
Resultado Operativo20,235.0037,272.003,359.00
Resultado Neto21,979.0031,372.002,119.00
Beneficio Básico por Acción3.925.590.38
Num Medio Acciones diluidas en circulación5,7085,7335,643
Balance
Activo Corriente59,693.0051,259.0043,333.00
Activos no corrientes121,782.00145,944.00183,168.00
Total Activo 181,476.00197,205.00226,501.00
Pasivo corriente42,671.0042,138.0047,794.00
Total Pasivo---
Capital Total77,201.0095,661.0089,014.00
Flujo de Caja
Flujo de caja operativo32,580.0029,267.008,700.00
Inversiones de Capital-2,711.00-3,236.00-3,907.00
Flujo de Caja Libre29,869.0026,031.004,793.00

En millones, excepto "EPS básico". La moneda es USD.

Perfil de la compañía

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Sector

Atención sanitaria

Industria

Fabricante de Medicamentos - General

Estilo de acciones

Grande-Valor

Fin Ejercicio Fiscal

diciembre

Empleados

88,000
Principales Características
Más...
Precio/Beneficio 12 m66.82
Precio/Valor contable1.62
Precio/Ventas TTM2.45
Crec Ingresos (media 3 a)11.76
Crec BPA (media 3 a)-
Margen operativo5.74
Margen neto3.62
ROE 12 m2.29
Deuda/Fondos propios0.68
Dividendos
AntÚltimo
Fecha declarada03/10/2314/12/23
Ex-Div09/11/2325/01/24
Pagado04/12/2301/03/24
Cantidad0.410.42
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures